<DOC>
	<DOCNO>NCT00135720</DOCNO>
	<brief_summary>The purpose study find effectiveness safety investigational drug call etanercept ( Enbrel ) treat pemphigus vulgaris . Pemphigus vulgaris potentially life threaten blister condition currently cure . An investigational drug one approve United States ( US ) Food Drug Administration ( FDA ) treat particular condition disease . Etanercept approve FDA treat rheumatoid arthritis , juvenile rheumatoid arthritis , psoriasis , pemphigus vulgaris .</brief_summary>
	<brief_title>Study Etanercept ( Enbrel ) Treatment Pemphigus Vulgaris</brief_title>
	<detailed_description>People pemphigus vulgaris find increased amount substance call tumor-necrosis factor-alpha ( TNF-alpha ) blood . Etanercept may control pemphigus vulgaris block effect TNF-alpha . Patients diagnose pemphigus vulgaris ask participate research study . Enrolled subject give either etanercept placebo . A placebo look like study drug contains active medication . Placebos help study doctor find effect study drug due drug study . This type study design help measure true effectiveness treatment . Patients 2 chance 3 receive etanercept 1 chance 3 receive placebo . The researcher expect enroll 24 subject study . Up 16 subject enrol Brigham Women 's Hospital ( BWH ) Massachusetts General Hospital ( MGH ) . This study sponsor Amgen , Inc. , manufacturer etanercept . If take part another research study take part research study last 28 day , patient able take part study . Patients multiple study simultaneously ; however , exception make non-invasive , non-interventional , observational study . This study last 16 week total 6 study visit : screening , week 0 ( baseline ) , week 2 , 4 , 8 16 . The participant able continue current medication pemphigus throughout study . All participant must least 18 year age clinical diagnosis pemphigus vulgaris least 6 active blister erosion . Neither pregnant nursing woman include study .</detailed_description>
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Summary Understand sign write informed consent form willing able comply procedure study Have clinical diagnosis pemphigus vulgaris Have least 6 active pemphigus lesion ( blister erosion ) Have adverse effect due combine etanercept concurrent pemphigus medication Be stable dose current pemphigus medication least one month Females childbearing potential must negative urine pregnancy test prior treatment agree practice acceptable method birth control ( oral contraceptive , hormonal implant device , DepoProvera , condom spermicide , diaphragm contraceptive cream foam , intrauterine device ) course study Be least 18 year old time enrollment Be able adhere study visit schedule protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Pemphigus Vulgaris</keyword>
	<keyword>Chronic Pemphigus</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Enbrel</keyword>
	<keyword>anti-TNF-alpha</keyword>
	<keyword>TNF-alpha antagonist</keyword>
	<keyword>biologic</keyword>
	<keyword>immunomodulator</keyword>
	<keyword>subcutaneous medication</keyword>
</DOC>